首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | CCL6 |
| Uniprot No | P27784 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-116aa |
| 氨基酸序列 | MRNSKTAISFFILVAVLGSQAGLIQEMEKEDRRYNPPIIHQGFQDTSSDCCFSYATQIPCKRFIYYFPTSGGCIKPGIIFISRRGTQVCADPSDRRVQRCLSTLKQGPRSGNKVIA |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL6重组蛋白的3篇示例文献(内容为模拟概括，实际文献需通过学术数据库查询)：
1. **文献名称**: "Expression and functional characterization of recombinant murine CCL6 in inflammatory models"
**作者**: Smith A, et al.
**摘要**: 本研究通过大肠杆菌系统表达并纯化重组小鼠CCL6蛋白，验证其体外趋化活性可诱导单核细胞迁移，并在小鼠肺部炎症模型中证实CCL6通过激活CCR1受体加剧中性粒细胞浸润。
2. **文献名称**: "CCL6 regulates myeloid-derived suppressor cells in tumor microenvironment"
**作者**: Li Y, et al.
**摘要**: 研究利用重组CCL6蛋白处理荷瘤小鼠，发现其通过上调STAT3信号通路促进髓系抑制细胞(MDSCs)扩增，进而抑制T细胞抗肿瘤免疫反应，提示CCL6在肿瘤免疫逃逸中的潜在作用。
3. **文献名称**: "Structural analysis of CCL6 reveals key residues for chemotactic activity"
**作者**: Garcia-Ruiz E, et al.
**摘要**: 通过核磁共振解析重组CCL6蛋白的三维结构，发现其N端β-发夹结构对结合受体CCR2至关重要，突变关键氨基酸(如Arg18)显著降低其趋化能力，为靶向CCL6的药物设计提供依据。
**注**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"CCL6 recombinant protein"或"recombinant CCL6 function")。小鼠CCL6研究较多，人类同源蛋白为CCL23.需注意物种差异。
CCL6 (C-C motif chemokine ligand 6), also known as C10 or MRP-1. is a small secretory protein belonging to the CC chemokine subfamily. It plays a role in immune regulation, inflammation, and cell migration by interacting with specific G protein-coupled receptors, such as CCR1. Structurally, CCL6 contains four conserved cysteine residues forming two disulfide bonds critical for its tertiary structure and bioactivity. It is primarily produced by macrophages, dendritic cells, and certain epithelial cells under inflammatory conditions.
Recombinant CCL6 is engineered using expression systems like *E. coli* or mammalian cells to produce purified, biologically active proteins for research and therapeutic development. Its production involves cloning the CCL6 gene into expression vectors, followed by purification via affinity chromatography. The recombinant form retains native functionality, enabling studies on chemotaxis, immune cell recruitment, and signaling pathways.
In vivo, CCL6 participates in host defense, wound healing, and pathological processes like fibrosis or tumor progression. Research highlights its dual roles: promoting macrophage infiltration in infection resolution while contributing to chronic inflammation in diseases such as asthma or rheumatoid arthritis. Recombinant CCL6 is widely used to investigate its mechanisms in disease models, screen anti-inflammatory drugs, or explore its potential as a biomarker. Despite progress, its receptor specificity and context-dependent effects in different tissues remain areas of active study, underscoring its complexity in immune modulation.
×
